Literature DB >> 9549518

The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.

L H Van den Berg1, H Franssen, J H Wokke.   

Abstract

We studied the long-term effect of intravenous immunoglobulin (IV Ig) treatment in seven patients with multifocal motor neuropathy. In six patients, treatment with a full IV Ig course (0.4 g/kg for 5 consecutive days) improved muscle strength but for not longer than 12 weeks. These patients received IV Ig maintenance treatment consisting of one infusion every week for 2-4 years. One patient in whom the effect of the initial full IV Ig treatment lasted for more than 1 year received incidental IV Ig treatment when muscle strength deteriorated. In all patients IV Ig treatment had a beneficial effect on most muscle groups during the follow-up period. However, in three of the seven patients muscle strength deteriorated during IV Ig maintenance treatment in four of the 28 muscle groups that had initially shown an improvement of muscle strength after the start of IV Ig treatment, and in two muscle groups with normal strength at the start of IV Ig treatment. The electrophysiological follow-up studies indicated that there was an improvement of conduction block, but also that there were new sites of conduction block and ongoing axonal degeneration during IV Ig maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549518     DOI: 10.1093/brain/121.3.421

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  15 in total

Review 1.  Molecular mechanisms regulating motor neuron development and degeneration.

Authors:  T J Kilpatrick; M Soilu-Hänninen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 3.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 4.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 5.  Multifocal motor neuropathy: current therapies and novel strategies.

Authors:  Eduardo Nobile-Orazio; Francesca Gallia
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

Review 6.  Treatment of dys-immune neuropathies.

Authors:  Eduardo Nobile-Orazio
Journal:  J Neurol       Date:  2005-04       Impact factor: 4.849

Review 7.  IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results.

Authors:  Eduardo Nobile-Orazio; Fabrizia Terenghi
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 8.  Initial and long-term management of autoimmune neuropathies.

Authors:  Carol Lee Koski
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Axon loss is an important determinant of weakness in multifocal motor neuropathy.

Authors:  J T H Van Asseldonk; L H Van den Berg; S Kalmijn; R M Van den Berg-Vos; C H Polman; J H J Wokke; H Franssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

10.  Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?

Authors:  L L Teunissen; H Franssen; J H J Wokke; Y van der Graaf; W H J P Linssen; J D Banga; D M Laman; N C Notermans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.